



Emerging Therapeutic Approaches to Esophageal Cancer

Guest Editors:

Dr. Pornima Phatak

1. Birmingham Veterans Affairs
Health Care System,
Birmingham, AL 35233, USA
2. Department of Surgery,
University of Alabama at
Birmingham, Birmingham, AL
35233, USA

Dr. James M. Donahue

1. Birmingham Veterans Affairs
Health Care System,
Birmingham, AL 35233, USA
2. Department of Surgery,
University of Alabama at
Birmingham, Birmingham, AL
35233, USA

Dr. Kaushal Asrani

Johns Hopkins School of
Medicine, Baltimore, MD, USA

Message from the Guest Editors

Dear Colleagues,

The incidence of esophageal cancer is continuously increasing and is one of the least studied and deadliest malignancies, worldwide. Due to a lack of early diagnosis, it often presents at an advanced stage. Currently, standard treatment for locally advanced esophageal cancer involves chemotherapy and/or radiation therapy prior to surgery. Despite this trimodality approach, survival remains very poor with a five-year survival rate of 20%. Thus, alternative therapeutic strategies that serve adjunctive roles to surgery are required to improve survival in esophageal cancer patients.

Dr. Pornima Phatak
Dr. James M. Donahue
Dr. Kaushal Asrani
Guest Editors

Deadline for manuscript
submissions:

closed (30 August 2023)





cancers



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
X@Cancers_MDPI